Suppr超能文献

一种基于磁共振成像的预后评分系统,用于预测适合移植的多发性骨髓瘤患者的预后。

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.

作者信息

Mai Elias K, Hielscher Thomas, Kloth Jost K, Merz Maximilian, Shah Sofia, Raab Marc S, Hillengass Michaela, Wagner Barbara, Jauch Anna, Hose Dirk, Weber Marc-André, Delorme Stefan, Goldschmidt Hartmut, Hillengass Jens

机构信息

Department of Internal Medicine V, University Hospital of Heidelberg, Heidelberg, Germany.

Division of Biostatistics, German Cancer Research Center, Heidelberg, Heidelberg, Germany.

出版信息

Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20.

Abstract

Diffuse and focal bone marrow infiltration patterns detected by magnetic resonance imaging have been shown to be of prognostic significance in all stages of monoclonal plasma cell disorders and have, therefore, been incorporated into the definition of the disease. The aim of this retrospective analysis was to develop a rapidly evaluable prognostic scoring system, incorporating the most significant information acquired from magnetic resonance imaging. Therefore, the impact of bone marrow infiltration patterns on progression-free and overall survival in 161 transplant-eligible myeloma patients was evaluated. Compared to salt and pepper/minimal diffuse infiltration, moderate/severe diffuse infiltration had a negative prognostic impact on both progression-free survival (P<0.001) and overall survival (P=0.003). More than 25 focal lesions on whole-body magnetic resonance imaging or more than seven on axial magnetic resonance imaging were associated with an adverse prognosis (progression-free survival: P=0.001/0.003 and overall survival: P=0.04/0.02). A magnetic resonance imaging-based prognostic scoring system, combining grouped diffuse and focal infiltration patterns, was formulated and is applicable to whole-body as well as axial magnetic resonance imaging. The score identified high-risk patients with median progression-free and overall survival of 23.4 and 55.9 months, respectively (whole-body-based). Multivariate analyses demonstrated that the magnetic resonance imaging-based prognostic score stage III (high-risk) and adverse cytogenetics are independent prognostic factors for both progression-free and overall survival (whole-body-based, progression-free survival: hazard ratio=3.65, P<0.001; overall survival: hazard ratio=5.19, P=0.005). In conclusion, we suggest a magnetic resonance imaging-based prognostic scoring system which is a robust, easy to assess and interpret parameter summarizing significant magnetic resonance imaging findings in transplant-eligible patients with multiple myeloma.

摘要

磁共振成像检测到的弥漫性和局灶性骨髓浸润模式已被证明在单克隆浆细胞疾病的各个阶段都具有预后意义,因此已被纳入该疾病的定义中。这项回顾性分析的目的是开发一种可快速评估的预后评分系统,纳入从磁共振成像中获取的最重要信息。因此,评估了161例适合移植的骨髓瘤患者骨髓浸润模式对无进展生存期和总生存期的影响。与椒盐样/轻度弥漫性浸润相比,中度/重度弥漫性浸润对无进展生存期(P<0.001)和总生存期(P=0.003)均有负面预后影响。全身磁共振成像上超过25个局灶性病变或轴向磁共振成像上超过7个局灶性病变与不良预后相关(无进展生存期:P=0.001/0.003;总生存期:P=0.04/0.02)。制定了一种基于磁共振成像的预后评分系统,该系统结合了分组的弥漫性和局灶性浸润模式,适用于全身及轴向磁共振成像。该评分系统识别出高危患者,其无进展生存期和总生存期的中位数分别为23.4个月和55.9个月(基于全身)。多变量分析表明,基于磁共振成像的预后评分、III期(高危)和不良细胞遗传学是无进展生存期和总生存期的独立预后因素(基于全身,无进展生存期:风险比=3.65,P<0.001;总生存期:风险比=5.19,P=0.005)。总之,我们建议一种基于磁共振成像的预后评分系统,它是一个强大、易于评估和解释的参数,总结了适合移植的多发性骨髓瘤患者磁共振成像的重要发现。

相似文献

1
A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.
Haematologica. 2015 Jun;100(6):818-25. doi: 10.3324/haematol.2015.124115. Epub 2015 Mar 20.
6
Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma.
J Clin Oncol. 2010 Mar 20;28(9):1606-10. doi: 10.1200/JCO.2009.25.5356. Epub 2010 Feb 22.
7
Bone marrow transplantation in patients with multiple myeloma: prognostic significance of MR imaging.
AJR Am J Roentgenol. 2001 Jan;176(1):91-6. doi: 10.2214/ajr.176.1.1760091.
10
Role of MRI for the diagnosis and prognosis of multiple myeloma.
Eur J Radiol. 2005 Jul;55(1):56-63. doi: 10.1016/j.ejrad.2005.01.017.

引用本文的文献

2
F-FDG PET/CT and MRI in the Management of Multiple Myeloma: A Comparative Review.
Front Nucl Med. 2022 Feb 22;1:808627. doi: 10.3389/fnume.2021.808627. eCollection 2021.
4
Imaging of Multiple Myeloma: Present and Future.
J Clin Med. 2024 Jan 2;13(1):264. doi: 10.3390/jcm13010264.
5
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.
Blood Cancer J. 2022 May 30;12(5):83. doi: 10.1038/s41408-022-00679-5.
6
Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma.
Radiol Imaging Cancer. 2021 Sep;3(5):e210048. doi: 10.1148/rycan.2021210048.
9
Quantitative and qualitative assessment of plasma cell dyscrasias in dual-layer spectral CT.
Eur Radiol. 2021 Oct;31(10):7664-7673. doi: 10.1007/s00330-021-07821-0. Epub 2021 Mar 30.

本文引用的文献

1
Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
J Clin Oncol. 2015 Feb 20;33(6):657-64. doi: 10.1200/JCO.2014.57.9961. Epub 2015 Jan 20.
2
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
7
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
Leukemia. 2014 May;28(5):1122-8. doi: 10.1038/leu.2013.313. Epub 2013 Oct 25.
8
Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance.
Leukemia. 2014 Jan;28(1):174-8. doi: 10.1038/leu.2013.244. Epub 2013 Aug 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验